California-based Graph AI, focused on patient safety and pharmacovigilance, announced its $3 million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.

Graph is a prime example of the new wave of AI-native challengers reshaping the pharma and life sciences landscape, especially the $8 billion pharmacovigilance market. Pharmacovigilance, mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report adverse drug events (ADE) across a drug's entire lifecycle.

Currently, pharma companies outsource this process to services firms, which deploy armies of individuals to scrape data from various sources and report ADEs manually. By keeping a human in the loop only for select, regulatory-mandated steps, Graph enables companies to transition from manual, error-prone, and time-intensive workflows to highly automated, AI-driven systems that enhance the efficiency and accuracy of medical reviews while ensuring regulatory compliance.

Founded in 2024, Graph is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), industry veterans with significant experience across leading global organisations, including Infosys, Google, and ServiceNow.